title: Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.
abstract: We have performed a prospective study to evaluate early chimerism and its kinetics after allogeneic peripheral blood stem cell transplantation among 68 patients who received a reduced-intensity conditioning (RIC) regimen with fludarabine plus melphalan (n=40) or busulphan (n=28). Chimerism was analyzed by polymerase chain reaction amplification of short tandem repeats in unfractionated (UF) and/or fractionated nucleated cells from bone marrow and peripheral blood (PB). All of the patients showed initial donor engraftment and no patient presented primary or secondary graft failure. In UF samples, the probability of achieving stable complete donor chimerism (CDC) in PB within the first 6 months was 70% on day +30, 85% on day +100 and 95% on day +180. CDC in granulocytes was observed in nearly all cases from day +30 onwards. CDC in T cells, however, differed among melphalan and busulphan recipients during the first 3 months (100 vs 0% on day +30 and 93 vs 20% on day +90, respectively). In multivariate analysis, the only significant variable associated with the achievement of early CDC was having received more than two lines of chemotherapy pretransplant (P<0.02). No correlation was found between the rate of achieving early CDC and the occurrence of acute graft-versus-host disease (GVHD) or disease progression post-transplant. In multivariate analysis, the only variable that influenced the incidence of disease progression post-transplant was the development of chronic extensive GVHD (P<0.05). In conclusion, a state of CDC is readily obtained within the first 6 months after our RIC protocols. Donor myeloid engraftment occurs rapidly in all cases, while early T-cell CDC is more common in more immunosuppressed hosts and, perhaps, in melphalan recipients.
authors.affiliation: Division of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Valcárcel
authors.forename: R
authors.initials: R
authors.lastname: Martino
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.forename: M V
authors.initials: MV
authors.lastname: Mateos
authors.forename: J A
authors.initials: JA
authors.lastname: Pérez-Simón
authors.forename: C
authors.initials: C
authors.lastname: Canals
authors.forename: F
authors.initials: F
authors.lastname: Fernández
authors.forename: J
authors.initials: J
authors.lastname: Bargay
authors.forename: E
authors.initials: E
authors.lastname: Muñiz-Díaz
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: J
authors.initials: J
authors.lastname: Sierra
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011446:Prospective Studies; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous